2023 Targeted Therapies of Lung Cancer Meeting

Call for Abstracts

Twitter feed is not available at the moment.

TTLC 2023 Abstract Submissions is Closed

The Scientific Program Committee for the IASLC 2023 Targeted Therapies of Lung Cancer Meeting is inviting the submission of scientific abstracts. Please read the details below carefully before submitting an abstract.

Important Deadlines

Call for Abstracts OpensNovember 1, 2022
Abstract Submission DeadlineDecember 2, 2022 (23:59 PST)
Author Notification of AcceptanceDecember 20, 2022
Presenting Author Registration DeadlineJanuary 20, 2023 (23:59 PST)
  • Oral Presentation (a maximum of four oral presentations will be selected, if you are not comfortable providing an oral presentation please only select poster presentation during submission)
  • Poster Presentation (abstracts not selected for oral presentation will be provided a poster presentation)

Only abstract submissions presented by Fellows, Residents & Junior Faculty within two years of appointment and from North America (Canada, USA, Mexico) will be accepted. Proof of fellowship, residence or faculty status (acceptance letter, university ID, letter of employment etc.) will be requested during abstract submission. These restrictions only apply to the lead author/presenter, more senior faculty and pharma company employees may be included as co-authors.

  • Research work should be original and innovative. Work can be presented prior to the IASLC 2023 Targeted Therapies of Lung Cancer Meeting but MUST include new information/data.
  • Abstract title must not exceed 75 words in length.
  • Abstracts must not exceed 500 words in length (not including title and authors).
  • Tables may be included, and each will count as 100 words.
  • A maximum of two images may be included; each will count as 100 words.
  • Tables, images and graphs must be uploaded in GIF, JPEG, JPG or PNG format at 300 dpi and 100% size. Any higher resolution is acceptable.
  • Abstracts must be structured with the following headings:
    • Background
    • Methods
    • Results
    • Conclusion
  • Please add the above headings (Background, Methods, Results, Conclusion) to each section of your abstract body.
  • Abstracts will be accepted in English only
  • There is no fee for submitting an abstract
  • There is no limit to the number of abstracts you may submit (however an individual may not be offered more than one poster or oral presentation)
  • All Abstracts accepted by the Scientific Program Committee will be published in the official meeting program book and on the conference website prior to the meeting and it is mandatory to agree to this at the time of submission

Step 1. Title, Topic and Presentation Type

  • The abstract title must not exceed 75 words in length.
  • Please select the desired topic for your abstract submission. The scientific program committee reserves the right to move the abstract to another topic should it be seen as a better fit.
  • Please note your preferred presentation format. If you would not be comfortable giving an oral presentation, please select Poster Only. NOTE: Selecting Poster/Oral does not guarantee you will be assigned an oral abstract presentation upon acceptance; the final presentation type is determined by the Scientific Program Committee

Step 2. Authors

  • Please enter the authors and affiliations of the abstract in title case.
  • Only abstract submissions from Junior Faculty (trainees, fellows, PhD students, faculty members in their first two years in an academic position and from North America (Canada, USA, Mexico)) will be accepted. Proof of junior faculty status (acceptance letter, university ID, letter of employment etc.) will be requested during abstract submission. These restrictions only apply to the lead author/presenter, more senior faculty and pharma company employees may be included as co-authors.
  • There is no limit to the number of co-authors per abstract
  • There is a limit of one presenting author per abstract
  • If more than two authors are listed, please select who the presenting author is.
  • The presenting author of an accepted abstract must be registered by January 21, 2023
  • Should a presenting author not be registered by the deadline the abstract may be removed from the program.

Step 3. Abstract Text

  • Do not include Title or Author data in the body of your abstract. Title and author should be entered in the steps above.
  • Abstracts may be entered directly into the site or copied and pasted
  • Research work should be original and innovative. Work can be presented prior to the IASLC 2023 Targeted Therapies of Lung Cancer Meeting, but MUST include new information/data
  • Abstracts must not exceed 500 words in length (not including title and authors)
  • Tables may be included, and each will count as 100 words
  • A maximum of two images may be included; each will count as 100 words
  • Tables, images and graphs must be uploaded in GIF, JPEG, JPG or PNG format at 300 dpi and 100% size. Any higher resolution is acceptable.
  • Abstracts must be structured with the following headings:
    • Background
    • Methods
    • Results
    • Conclusion
  • Please add the above headings (Background, Methods, Results, Conclusion) to each section of your abstract body. These headings will not count towards your word limit of 500.

Step 4. Preview & Submit

  • Please proofread your submission prior to submitting
  • Once an abstract is submitted it cannot be deleted, modified or corrected in the system after submission. All submitted abstracts will be published exactly as submitted.
  • Any abstracts in “Draft” status after the submission deadline has passed will not be considered for review. It is the abstract submitters responsibility to ensure that all abstracts you wish to be reviewed have been properly submitted.
  • Should you need to withdraw a submitted abstract, please contact [email protected]. Please include the abstract number and abstract title in your email.
  • Please carefully review the affiliation of all your co-authors as this is how it will appear in the conference program book as well as on the conference website.
  • You will be asked to review and agree to the abstract submission terms & conditions prior to submitting your abstract. Please read the information carefully.

For inquiries, please contact [email protected]. If your inquiry is regarding a particular draft or submission, please include the abstract number and title in your email.

Definition: Ongoing trials that have not reached pre-specified endpoints for analysis.

The submission of Clinical Trials in Progress is acceptable.

For any program and abstract related questions, please contact [email protected].